F-Star, previously backed by Merck Serono Ventures, signed a deal with the corporate venturing unit’s Germany-based parent, Merck Serono, yesterday to collaborate on the discovery and development of treatments for inflammatory disease. The tie-up could be worth more than €492m ($691.4m) to F-Star if it meets certain milestones, and it would also be eligible for…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
